M05 M06
Conditions
Interventions
Group 1: RABBIT is a independent, academically led, longitudinal cohort study of patients with rheumatoid arthritis (RA) in routine rheumatology care, which aims to investigate long-term safety and ef
Sponsors
Deutsches Rheuma-Forschungszentrum Berlin
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Confirmed diagnosis of rheumatoid arthritis - At least 18 years of age at inclusion - Onset of rheumatoid arthritis after 16 years of age - Starting new therapy with an approved bDMARD (biologic Disease Modifying Anti-Rheumatic Drug) or tsDMARD (targeted synthetic Disease Modifying Anti-Rheumatic Drug) respectively with a new csDMARD (conventional synthetic Disease Modifying Anti-Rheumatic Drug) after at least one csDMARD failure or addition of a csDMARD to an existing basic therapy
Exclusion criteria
Exclusion criteria: Patients with arthritis in the context of another autoimmune disease in the foreground, such as collagenosis or vasculitis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Investigation of the long-term safety and effectiveness of new anti-rheumatic therapies in clinical practice, also in comparison to conventional synthetic DMARD therapy. For this purpose, the disease and therapy courses of patients with rheumatoid arthritis in routine rheumatological care will be documented over at least 5 years, ideally over 10 years. | — |
Secondary
| Measure | Time frame |
|---|---|
| patient reported outcomes health care consumption and work disability drug survival comorbidity | — |
Countries
Germany
Contacts
Public ContactAnja Strangfeld
Deutsches Rheuma-Forschungszentrum
Outcome results
None listed